Allogeneic BCMA/CD19 CAR-T (umbilical cord blood-derived)

Allogeneic CAR-T cell therapy targeting BCMA and CD19

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allogeneic BCMA/CD19 CAR-T (umbilical cord blood-derived), covering 2025-11-25 to 2025-11-25. Get the full timeline:

Most recent: Clinical Trial Update: Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma [Phase 1]

See pricing